Phase I CHRYSALIS: Amivantamab, an EGFR-MET Bispecific Antibody, in Advanced NSCLC with MET Exon 14 Skipping Mutations

September 8-14, 2021; Virtual Meeting
Phase I results suggest promising clinical activity with amivantamab in unresectable or metastatic NSCLC driven by a MET exon 14 skipping mutation.
Format: Microsoft PowerPoint (.ppt)
File Size: 239 KB
Released: September 23, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Daiichi Sankyo, Inc.
Janssen Pharmaceutica NV
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme
Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Related Content

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Text module presenting a pharmacist’s perspective on toxicities with neoadjuvant/adjuvant immunotherapy for early-stage NSCLC from Clinical Care Options (CCO)

Stefanie Houseknecht, PharmD, BCOP Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: October 13, 2021 Expired: October 12, 2022

Slideset presenting a pharmacist’s perspective on toxicities with neoadjuvant/adjuvant immunotherapy for early-stage NSCLC from Clinical Care Options (CCO)

Stefanie Houseknecht, PharmD, BCOP Released: October 13, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue